VIDA streamlines respiratory clinical trials with artificial intelligence
November 22, 2021
VIDA Diagnostics, Inc. (VIDA), based in Coralville, has unveiled a new AI-powered portal, further removing friction in respiratory clinical trials.
Welcome to the University of Iowa Research Park, where collaborative opportunities in technology abound.
We offer corporations locating at the Park convenient, sustained access to the extensive, relevant research resources of The University of Iowa.
Here, growing enterprises have access to a state-of-the art business incubator, world-class research facilities and a dynamic faculty of scientists, physicians and engineers at one of the world’s leading public research universities.
News & Announcements
VIDA Streamlines Respiratory Clinical Trials with Artificial Intelligence (AI)
CORALVILLE, Iowa, Nov. 16, 2021 /PRNewswire/ -- VIDA Diagnostics, Inc. (VIDA) is further removing friction in respiratory clinical trials with the introduction of a new AI-powered portal. The cloud-based VIDA Intelligence Portal (VIP) streamlines challenges often associated with imaging in trials such as site onboarding, staff training, image data management, and data quality. Leveraging a powerful AI engine, the portal automates cumbersome and time sensitive tasks such as subject anonymization and quality control workflow processes.
Viewpoint Molecular Targeting™ Receives FDA Clearance of Investigational New Drug Application for Phase 1 Imaging Study for VMT-a-NET for Neuroendocrine Tumors
– VMT-a-NET Phase 1 imaging study to be followed by Phase 1/2a therapy study for the
treatment of neuroendocrine tumors being conducted at the University of Iowa –
– Preclinical efficacy results demonstrated VMT-a-NET to significantly inhibit tumor
growth and improve survival compared to untreated controls –
– VMT-a-NET imaging study provisional results expected in Q4 2021 –
Events
There are currently no results to display.